<DOC>
	<DOCNO>NCT00169182</DOCNO>
	<brief_summary>The purpose study compare two regimen chemotherapy use first treatment patient larynx hypopharynx tumor would treat total laryngectomy . The standard treatment combination 2 drug ( Cisplatin 5FU ) . The aim study evaluate potential benefit addition third drug ( Docetaxel ) chemotherapy regimen . Patients receive 3 cycle chemotherapy . Responders induction treatment treat radiation purpose larynx preservation . Non responders patient treat total laryngectomy .</brief_summary>
	<brief_title>Induction CT Cisplatin , 5FU With Without Docetaxel Patients With T3 T4 Larynx Hypopharynx Carcinoma</brief_title>
	<detailed_description>The purpose study compare two regimen induction chemotherapy patient T3 T4 larynx hypopharynx carcinoma would treat total laryngectomy . The aim study compare standard regimen ( Cisplatin + 5FU ) versus TPF regimen ( Taxotere + Cisplatin + 5FU ) . Responders induction treatment treat radiation purpose larynx preservation . Non responders patient treat total laryngectomy follow postoperative radiation .</detailed_description>
	<mesh_term>Laryngeal Diseases</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Hypopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>T3 T4 larynx hypopharynx tumor would treat total laryngectomy Biopsy proven carcinoma Adequate biology Performance status 0 1 Larynx hypopharynx tumor could treat partial laryngectomy Distant metastasis Prior surgery , chemotherapy radiation Intercurrent disease contra indication chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Larynx cancer</keyword>
	<keyword>Hypopharynx cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Randomized trial</keyword>
	<keyword>Larynx preservation</keyword>
</DOC>